Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Tolerance Induction in Living Donor Kidney Transplantation
NCT03292445Phase 1Unknown
- Start
- Feb 2017
- Primary completion
- Feb 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of donor blood stem cells + T cells in kidney transplant rejection. Primary endpoint: Reduction of dependence on immunosuppressive drugs to prevent graft rejection at 24 months. Status: unknown.
02
Drugs
donor blood stem cells + T cells
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03292445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292445.